Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

An avalanche of lawsuits filed against Bayer in Missouri is pitting the chemical maker against trial attorneys and cancer patients.

Bayer pharma chief sees no big acquisitions in near future January 14, 2025 Leaders Bayern Munich should have scored several more goals in their 1-0 Bundesliga win at Borussia Moenchengladbach on ...

Bayer expects its pharmaceutical business to return to growth in 2027, unit President Stefan Oelrich said Monday. The German conglomerate is planning to launch new therapies — one that treats a ...

Despite challenges in the Crop Science division, the strength of the Pharmaceuticals division and steady performance in Consumer Health are encouraging. Moreover, Bayer recently scored an ...

The pharmaceutical company’s latest partnership with Incremental and Skai drove a 32% boost in iROI, delivering nearly a third more sales per ad dollar.

Kepler Capital analyst Christian Faitz maintained a Hold rating on Bayer (0P6S – Research Report) on January 21 and set a price target of ...

Gadoquatrane, a contrast agent Bayer is developing for use in MRI scans, like those done in MS, uses 60% less gadolinium and ...

Oelrich said there was also no reason to split Bayer, whose businesses span agrochemicals, pharmaceuticals and non-prescription drugs. "We function with three very independent businesses," he said.